On November 17, 2022, the FDA announced the approval of TZIELDTM (teplizumab-mzwv), which is a CD-3 directed monoclonal antibody. This first-in-class therapy is intended to delay…
New Meds and Tech from PES Drugs and Therapeutics committee In June 2022, the Food and Drug Administration (FDA) approved a supplemental indication for Qsymia (phentermine…
New Meds and Tech from PES Drugs and Therapeutics committee The FreeStyle Libre 3 is the third generation of Abbot Laboratories’ continuous glucose monitoring system intended…
New Meds and Tech from PES Drugs and Therapeutics committee The Omnipod 5 (Insulet Inc) is a hybrid closed-loop system approved by the FDA on January…
New Meds and Tech from PES Drugs and Therapeutics committee PES Drug Alert – GnRH agonists On July 1, 2022 the Food and Drug Administration (FDA)…
Update to the Vosoritide (Voxzogo TM) indication in USA On October 20, 2023 US Food and Drug Administration (FDA) has extended approval of Voxzogo to children…
New Meds and Tech from PES Drugs and Therapeutics committee SKYTROFA® Anna Ryabets-Lienhard, DO, Christine Yu, MD, Emily Breidbart, MD In August 2021, FDA approved…
EVOLOCUMAB (REPATHA) Brenda Kohn MD, Dania Al-Hamad MD, Ambika P. Ashraf MD On September 24, 2021, Amgen announced that the FDA approved evolocumab (Repatha) as an adjunct…
Prepared on behalf of the PES Drugs and Therapeutics Committee by Kristal Matlock, MD, Dania Al-Hamad, MD, Vandana Raman, MD and Amit Lahoti, MD FDA approval…
Brief Therapeutic Update from PES Drugs and Therapeutics Committee (THYQUIDITYTM) THYQUIDITYTM is a liquid levothyroxine preparation that is FDA approved for (i) treatment of congenital or…